Clinical Trial Categories
Endometrial Trials
Trial ID ESR 22-21698 (EIMPRIS)
NCT05438498clinicaltrials.gov ID
Phase II/III
Trial ID 21461
NCT05173987clinicaltrials.gov ID
USOR ID: 21461
Phase III
A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting